# Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

> **NCT07077525** · PHASE4 · COMPLETED · sponsor: **Al-Azhar University** · enrollment: 196 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **COMBINATION_PRODUCT:** Dapagliflozin + Metformin
- **COMBINATION_PRODUCT:** Vildagliptin + Metformin

## Key facts

- **NCT ID:** NCT07077525
- **Lead sponsor:** Al-Azhar University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2024-08-10
- **Final completion:** 2024-08-31
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07077525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07077525, "Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07077525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*